Matisse Capital Solid Biosciences Inc. Transaction History

Matisse Capital

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 04, 2022	SELL	$1.69 - $2.46 $26,195 - $38,130	-15,500 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$3.49 - $5.51 $6,980 - $11,020	-2,000 Reduced 11.43%	15,500 $57,000
Q1 2021 May 14, 2021	BUY	$5.37 - $10.72 $10,740 - $21,440	2,000 Added 12.9%	17,500 $96,000
Q4 2020 Feb 12, 2021	SELL	$3.08 - $7.79 $27,720 - $70,110	-9,000 Reduced 36.73%	15,500 $117,000
Q2 2020 Jul 28, 2020	SELL	$2.1 - $3.42 $52,500 - $85,500	-25,000 Reduced 50.51%	24,500 $72,000
Q1 2020 May 07, 2020	SELL	$2.31 - $4.43 $7,854 - $15,061	-3,400 Reduced 6.43%	49,500 $118,000
Q4 2019 Feb 12, 2020	SELL	$2.82 - $12.9 $45,120 - $206,400	-16,000 Reduced 23.22%	52,900 $235,000
Q3 2019 Oct 28, 2019	BUY	$4.33 - $11.64 $12,557 - $33,756	2,900 Added 4.39%	68,900 $712,000
Q2 2019 Aug 13, 2019	BUY	$4.6 - $10.13 $1,380 - $3,039	300 Added 0.46%	66,000 $380,000
Q1 2019 Apr 24, 2019	BUY	$7.19 - $32.37 $472,383 - $2.13 Million	65,700 New	65,700 $604,000
Q4 2018 Jan 18, 2019	SELL	$21.32 - $46.34 $172,692 - $375,354	-8,100 Closed	0 $0
Q3 2018 Oct 30, 2018	BUY	$36.35 - $51.7 $294,435 - $418,770	8,100 New	8,100 $382,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $36.5M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Matisse Capital, based on Form 13F filings with the SEC.

Stay updated on Matisse Capital with notifications on news.